Jump to content

A-PONASA

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Innerstream (talk | contribs) at 15:15, 24 October 2024. The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
A-PONASA
Identifiers
  • N-(adamantan-1-yl)-4-(pentyloxy)naphthalene-1-sulfonamide
Chemical and physical data
FormulaC25H33NO3S
Molar mass427.60 g·mol−1
3D model (JSmol)
  • CCCCCOc1ccc(c2ccccc21)S(=O)(=O)NC12CC3CC(C1)CC(C2)C3
  • InChI=1S/C25H33NO3S/c1-2-3-6-11-29-23-9-10-24(22-8-5-4-7-21(22)23)30(27,28)26-25-15-18-12-19(16-25)14-20(13-18)17-25/h4-5,7-10,18-20,26H,2-3,6,11-17H2,1H3
  • Key:KDLJELWGBJUNBO-UHFFFAOYSA-N

A-PONASA is a synthetic cannabinoid receptor agonist that has been sold as a designer drug. It is closely related to the previously reported compound CB-13 but with the naphthalene head group replaced with adamantyl, and an unusual sulfonamide linker group.[1][2]

See also

[edit]

References

[edit]
  1. ^ "Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms" (PDF). Advisory Council on the Misuse of Drugs. 2022.
  2. ^ Andrews R, Jorge R, Christie R, Gallegos A (April 2023). "From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day". Drug Testing and Analysis. 15 (4): 378–387. doi:10.1002/dta.3422. PMID 36507715. S2CID 254610773.